Role of HIV on Glutathione Synthesis and Oxidative Stress
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
HIV infection is associated the development of increased oxidative stress and deficiency of glutathione (GSH), the dominant endogenous antioxidant protein, but the underlying mechanisms contributing to GSH deficiency are hitherto unknown. Furthermore GSH metabolism has not been studied in HIV patients, in whom the burden of risk factors promoting oxidative stress is highest. Our previous studies in non-HIV human subjects with diabetes-related oxidative stress and GSH deficiency have demonstrated that the latter is due to decreased synthesis of GSH. Importantly, short-term dietary supplementation with the simple GSH precursor amino-acids cysteine and glycine, boosted GSH synthesis and cellular concentrations, corrected GSH deficiency, and reduced oxidative stress and oxidant damage. The current proposal will study whether (1) defective synthesis underlies GSH deficiency in patients with HIV, and will test a simple, inexpensive and rational therapy based on protein supplementation to improve GSH synthesis and concentrations and lower markers of oxidative stress and oxidant damage in these patients; (2) study if correction of GSH deficiency is asssociated with any changes in (a) impaired mitochondrial fuel oxidation in the fasted and insulin stimulated states; (b) insulin sensitivity; (c) body composition and anthropometry; (d) forearm muscle strength; (e) plasma biochemistry, and (f) quality of life indices in these subjects.
| Condition | Intervention | Phase |
|---|---|---|
|
HIV Infection Erythrocyte Glutathione Deficiency |
Dietary Supplement: Cysteine (as n-acetylcysteine) and glycine Dietary Supplement: Cysteine/glycine |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Pharmacokinetics/Dynamics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Role of HIV on Glutathione Synthesis and Oxidative Stress |
- Glutathione synthesis rates and concentrations [ Time Frame: 9 hours ] [ Designated as safety issue: No ]Fractional and absolute synthesis rates of glutathione and its concentrations
- Mitochondrial fuel oxidation [ Time Frame: Twice over 9 hours of the study on 2 occassions ] [ Designated as safety issue: No ]Lipolysis, fuel oxidation, and a hyperinsulinemic euglycemic clamp.
- Rates of fuel kinetics [ Time Frame: 3 hours ] [ Designated as safety issue: No ]Measure rate of lipolysis (from infused 13C-palmitate) and recovery of 13CO2 (from infused acetate tracer)
- Insulin sensitivity [ Time Frame: 3 hours ] [ Designated as safety issue: No ]Measure insulin sensitivity using a hyperglycemic euglycemic clamp
- Muscle strength [ Time Frame: Done once in each 9-hour study ] [ Designated as safety issue: No ]
- Quality of life by SF36 questionnaire [ Time Frame: Before and after ] [ Designated as safety issue: No ]
| Enrollment: | 10 |
| Study Start Date: | August 2010 |
| Study Completion Date: | September 2011 |
| Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Cysteine/glycine
Subjects will be studied before and after receiving oral cysteine (as n-acetylcysteine) and glycine for 2 weeks
|
Dietary Supplement: Cysteine (as n-acetylcysteine) and glycine
Cysteine and glycine will be supplemented at doses of 0.81 mmol/kg/d and 1.31 mmol/kg/d for 2 weeks each
Dietary Supplement: Cysteine/glycine
Subjects will receive oral dietary amino-acids (cystiene as n-acetylcysteine, and glycine)
|
Eligibility| Ages Eligible for Study: | 21 Years to 70 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
(1) HIV infected patients with GSH deficiency
Exclusion Criteria:
- renal impairment (serum Creatinine above 1.5mg/dL), liver impairment (ALT and AST > 2x upper limit of normal)
- any hormonal disorders such as hypothyroidism, hypercortisolemia, hypogonadism, or diabetes mellitus on pharmacotherapy
- evidence of infections other than HIV in the preceding 3 months
- subjects with plasma triglyceride concentrations of ≥ 500mg/dL on triglyceride lowering therapy
- BMI < 20
- established heart disease
- Co-existing viral hepatitis B and C
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Rajagopal Sekhar, Associate Professor, Baylor College of Medicine |
| ClinicalTrials.gov Identifier: | NCT01355198 History of Changes |
| Other Study ID Numbers: | HIV and glutathione |
| Study First Received: | March 30, 2011 |
| Last Updated: | February 5, 2013 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Acetylcysteine N-monoacetylcystine Glycine |
Antiviral Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Expectorants Respiratory System Agents Free Radical Scavengers Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Antidotes Glycine Agents Neurotransmitter Agents |
ClinicalTrials.gov processed this record on May 16, 2013